Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Feb 18

PMID 26886260

Citations 69

Authors

Scooter Willis

Victor M Villalobos

Olivier Gevaert

Mark Abramovitz

Casey Williams

Branimir I Sikic

Brian Leyland-Jones

Affiliations

Soon will be listed here.

Abstract

Purpose: To discover novel prognostic biomarkers in ovarian serous carcinomas.

Methods: A meta-analysis of all single genes probes in the TCGA and HAS ovarian cohorts was performed to identify possible biomarkers using Cox regression as a continuous variable for overall survival. Genes were ranked by p-value using Stouffer's method and selected for statistical significance with a false discovery rate (FDR) <.05 using the Benjamini-Hochberg method.

Results: Twelve genes with high mRNA expression were prognostic of poor outcome with an FDR <.05 (AXL, APC, RAB11FIP5, C19orf2, CYBRD1, PINK1, LRRN3, AQP1, DES, XRCC4, BCHE, and ASAP3). Twenty genes with low mRNA expression were prognostic of poor outcome with an FDR <.05 (LRIG1, SLC33A1, NUCB2, POLD3, ESR2, GOLPH3, XBP1, PAXIP1, CYB561, POLA2, CDH1, GMNN, SLC37A4, FAM174B, AGR2, SDR39U1, MAGT1, GJB1, SDF2L1, and C9orf82).

Conclusion: A meta-analysis of all single genes identified thirty-two candidate biomarkers for their possible role in ovarian serous carcinoma. These genes can provide insight into the drivers or regulators of ovarian cancer and should be evaluated in future studies. Genes with high expression indicating poor outcome are possible therapeutic targets with known antagonists or inhibitors. Additionally, the genes could be combined into a prognostic multi-gene signature and tested in future ovarian cohorts.

Citing Articles

Role of the human cytochrome b561 family in iron metabolism and tumors (Review).

Zhou X, An Z, Lei H, Liao H, Guo X Oncol Lett. 2025; 29(3):111.

PMID: 39802312 PMC: 11718626. DOI: 10.3892/ol.2024.14857.

PAXIP1 is regulated by NRF1 and is a prognosis‑related biomarker in hepatocellular carcinoma.

Cheng Q, Han X, Xie H, Liao Y, Wang F, Cui X Biomed Rep. 2025; 22(3):38.

PMID: 39781045 PMC: 11704871. DOI: 10.3892/br.2024.1916.

CYB561 a potential prognostic biomarker for liver hepatocellular carcinoma.

Zhao Y, Du J, Zhuo J, Zhang Q, Dai L, Tang Y Clin Exp Med. 2024; 25(1):23.

PMID: 39708189 PMC: 11663187. DOI: 10.1007/s10238-024-01522-w.

Development of a prognostic model based on lysosome-related genes for ovarian cancer: insights into tumor microenvironment, mutation patterns, and personalized treatment strategies.

Sun R, Li S, Ye W, Lu Y Cancer Cell Int. 2024; 24(1):419.

PMID: 39702158 PMC: 11661007. DOI: 10.1186/s12935-024-03586-w.

Expression quantitative trait loci influence DNA damage-induced apoptosis in cancer.

Bigge J, Koebbe L, Giel A, Bornholdt D, Buerfent B, Dasmeh P BMC Genomics. 2024; 25(1):1168.

PMID: 39623312 PMC: 11613471. DOI: 10.1186/s12864-024-11068-6.

References

Riester M, Wei W, Waldron L, Culhane A, Trippa L, Oliva E . Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014; 106(5). PMC: 4580556. DOI: 10.1093/jnci/dju048. View

Bonome T, Levine D, Shih J, Randonovich M, Pise-Masison C, Bogomolniy F . A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008; 68(13):5478-86. PMC: 7039050. DOI: 10.1158/0008-5472.CAN-07-6595. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Bentink S, Haibe-Kains B, Risch T, Fan J, Hirsch M, Holton K . Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One. 2012; 7(2):e30269. PMC: 3278409. DOI: 10.1371/journal.pone.0030269. View

Bonome T, Lee J, Park D, Radonovich M, Pise-Masison C, Brady J . Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005; 65(22):10602-12. DOI: 10.1158/0008-5472.CAN-05-2240. View

Crijns A, Fehrmann R, de Jong S, Gerbens F, Meersma G, Klip H . Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009; 6(2):e24. PMC: 2634794. DOI: 10.1371/journal.pmed.1000024. View

Baker T, Piver M . Etiology, biology, and epidemiology of ovarian cancer. Semin Surg Oncol. 1994; 10(4):242-8. DOI: 10.1002/ssu.2980100403. View

Hernandez L, Hsu S, Davidson B, Birrer M, Kohn E, Annunziata C . Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010; 70(10):4005-14. PMC: 2873166. DOI: 10.1158/0008-5472.CAN-09-3912. View

10.

Waldron L, Haibe-Kains B, Culhane A, Riester M, Ding J, Wang X . Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst. 2014; 106(5). PMC: 4580554. DOI: 10.1093/jnci/dju049. View

11.

Sabatier R, Finetti P, Bonensea J, Jacquemier J, Adelaide J, Lambaudie E . A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer. 2011; 105(2):304-11. PMC: 3142802. DOI: 10.1038/bjc.2011.219. View

12.

Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H . High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res. 2012; 18(5):1374-85. DOI: 10.1158/1078-0432.CCR-11-2725. View

13.

Ibeanu O, Bristow R . Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer. 2010; 20 Suppl 1:S1-11. DOI: 10.1111/IGC.0b013e3181cff38b. View

14.

C Mok S, Bonome T, Vathipadiekal V, Bell A, Johnson M, Wong K . A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009; 16(6):521-32. PMC: 3008560. DOI: 10.1016/j.ccr.2009.10.018. View

15.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

16.

Gyorffy B, Lanczky A, Szallasi Z . Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2):197-208. DOI: 10.1530/ERC-11-0329. View

17.

Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, Konsgen D . A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol. 2009; 218(2):273-80. DOI: 10.1002/path.2547. View

18.

Nolen B, Lokshin A . Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol. 2011; 8(1):55-71. PMC: 3312922. DOI: 10.2217/fon.11.135. View

19.

Chang S, Bristow R, Ryu H . Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012; 19(13):4059-67. DOI: 10.1245/s10434-012-2446-8. View

20.

Verhaak R, Tamayo P, Yang J, Hubbard D, Zhang H, Creighton C . Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2012; 123(1):517-25. PMC: 3533304. DOI: 10.1172/JCI65833. View